Vyvgart Hytrulo Challenges the Step Therapy Model in Treatment-Naive CIDP
Episode Summary
Post hoc ADHERE analysis shows Vyvgart Hytrulo delivers early responses in 87.5% of treatment-naive CIDP patients, challenging step-therapy policies and prompting reconsideration of first-line treatment strategies.